Your browser doesn't support javascript.
loading
Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.
Hakariya, Hayase; Ohnishi, Mutsuko; Tanimoto, Tetsuya.
Affiliation
  • Hakariya H; Interfaculty Institute of Biochemistry, University of Tuebingen, Tuebingen, Germany.
  • Ohnishi M; Institute for Pharmaceutical and Social Health Sciences, Kyoto, Japan.
  • Tanimoto T; Medical Governance Research Institute, Tokyo, Japan.
Diabetes Obes Metab ; 26(8): 3006-3008, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38747140
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Universal Health Insurance / Glucagon-Like Peptides Limits: Humans Country/Region as subject: Asia Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2024 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Universal Health Insurance / Glucagon-Like Peptides Limits: Humans Country/Region as subject: Asia Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2024 Document type: Article Affiliation country: